Company: STAA
Filing Date: 2025-10-20
Form Type: DEFA14A
Source: 0001193125-25-243044
Chunk: 3

Company: STAAR SURGICAL CO
Filing Date: 2025-10-20
Form: DEFA14A
Chunk 3
---
 third quarter 2025, in each case upon receipt of corresponding payment. While the remaining $25.9 million related to the shipment was recognized in full during the third quarter 2025, the associated ICL procedures took place throughout 2025. Sales for the nine months ended September 26, 2025 were lower than the prior year period as distributors in China reduced their inventory by approximately $80 million to $85 million instead of purchasing new product from the Company. As of September 26, 2025, the Company believes its distributors in China maintained owned inventory at approximately six months, aligned to contractual levels. The financial information in this release is unaudited and subject to adjustment and confirmation as the Company completes its quarterly review and finalizes its financial statements to be filed with the Company’s Quarterly Report on Form 10-Qfor the quarter ended September 26, 2025, and the review of the Company’s independent registered public accounting firm’s consolidated financial statements for the quarterly period.

Stockholders with questions about voting their shares should contact STAAR’s proxy solicitor, Innisfree M&A Incorporated:

| • |     | For stockholders: +1 877-750-8233 
 (toll-free)                       |

| • |     | For banks and brokerage firms: +1 
 212-750-5833                      |

About STAAR Surgical STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer ®Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL’s are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye’s natural crystalline lens. Its EVO ICL ™product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3 million ICLs in over 75 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit www.EVOICL.com. To learn more about STAAR, visit www.staar.com. Additional Information About the Merger and Where to Find It This